Engineered immunological niches to monitor disease activity and treatment efficacy in relapsing multiple sclerosis.


Journal

Nature communications
ISSN: 2041-1723
Titre abrégé: Nat Commun
Pays: England
ID NLM: 101528555

Informations de publication

Date de publication:
03 08 2020
Historique:
received: 16 09 2019
accepted: 09 07 2020
entrez: 5 8 2020
pubmed: 5 8 2020
medline: 9 9 2020
Statut: epublish

Résumé

Relapses in multiple sclerosis can result in irreversible nervous system tissue injury. If these events could be detected early, targeted immunotherapy could potentially slow disease progression. We describe the use of engineered biomaterial-based immunological niches amenable to biopsy to provide insights into the phenotype of innate immune cells that control disease activity in a mouse model of multiple sclerosis. Differential gene expression in cells from these niches allow monitoring of disease dynamics and gauging the effectiveness of treatment. A proactive treatment regimen, given in response to signal within the niche but before symptoms appeared, substantially reduced disease. This technology offers a new approach to monitor organ-specific autoimmunity, and represents a platform to analyze immune dysfunction within otherwise inaccessible target tissues.

Identifiants

pubmed: 32747712
doi: 10.1038/s41467-020-17629-z
pii: 10.1038/s41467-020-17629-z
pmc: PMC7398910
doi:

Types de publication

Journal Article Research Support, N.I.H., Extramural Research Support, Non-U.S. Gov't

Langues

eng

Sous-ensembles de citation

IM

Pagination

3871

Subventions

Organisme : NIBIB NIH HHS
ID : R01 EB013198
Pays : United States
Organisme : NCI NIH HHS
ID : R01 CA243916
Pays : United States
Organisme : NINDS NIH HHS
ID : R01 NS099334
Pays : United States
Organisme : NIDDK NIH HHS
ID : R01 DK121462
Pays : United States
Organisme : NIAID NIH HHS
ID : R01 AI148076
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI147677
Pays : United States
Organisme : NIDDK NIH HHS
ID : P30 DK020572
Pays : United States
Organisme : NIDCR NIH HHS
ID : T32 DE007057
Pays : United States
Organisme : NIAID NIH HHS
ID : R21 AI142059
Pays : United States

Références

Zerhouni, E. Progress in Autoimmune Diseases Research. 4–5 https://www.niaid.nih.gov/sites/default/files/adccfinal.pdf (2005).
Hauser, S. L. & Oksenberg, J. R. The neurobiology of multiple sclerosis: genes, inflammation, and neurodegeneration. Neuron. 52, 61–76 (2006).
pubmed: 17015227
Wingerchuk, D. M. & Weinshenker, B. G. Disease modifying therapies for relapsing multiple sclerosis. Br. Med. J. 354, i3518 (2016).
Metz, I. et al. Pathologic heterogeneity persists in early active multiple sclerosis lesions. Ann. Neurol. 75, 728–738 (2014).
pubmed: 24771535 pmcid: 4070313
Lucchinetti, C. et al. Heterogeneity of multiple sclerosis lesions. Ann. Neurol. 47, 707–717 (2000).
pubmed: 10852536
Breiman, L. Random Forests. Mach. Learn. 45, 5–32 (2001).
Alter, O., Brown, P. O. & Botstein, D. Singular value decomposition for genome-wide expression data processing and modeling. Proc. Natl Acad. Sci. USA 97, 10101–10106 (2000).
pubmed: 10963673
Rao, S. S. et al. Enhanced survival with implantable scaffolds that capture metastatic breast cancer cells in vivo. Cancer Res. 76, 5209–5218 (2016).
pubmed: 27635043 pmcid: 5027988
Navegantes, K. C. et al. Immune modulation of some autoimmune diseases: the critical role of macrophages and neutrophils in the innate and adaptive immunity. J. Transl. Med. 15, 36 (2017).
pubmed: 28202039 pmcid: 5312441
Yan, Z., Gibson, S. A., Buckley, J. A., Qin, H. & Benveniste, E. N. Role of the JAK / STAT signaling pathway in regulation of innate immunity in neuroinflammatory diseases. Clin. Immunol. 189, 4–13 (2018).
pubmed: 27713030
Mayo, L., Quintana, F. J. & Weiner, H. L. The innate immune system in demyelinating disease. Immunol. Rev. 248,170–187 (2012).
pubmed: 22725961 pmcid: 3383669
Robinson, A. P., Harp, C. T., Noronha, A. & Miller, S. D. The experimental autoimmune encephalomyelitis (EAE) model of MS: utility for understanding disease pathophysiology and treatment. Mult. Scler. Relat. Disord. 122, 173–189 (2014).
Ramanathan, M. et al. In vivo gene expression revealed by cDNA arrays: the pattern in relapsing—remitting multiple sclerosis patients compared with normal subjects. J. Neuroimmunol. 116, 213–219 (2001).
pubmed: 11438176
Nickles, D. et al. Blood RNA profiling in a large cohort of multiple sclerosis patients and healthy controls. Hum. Mol. Genet. 22, 4194–4205 (2013).
pubmed: 23748426 pmcid: 3781642
Comabella, M. & Martin, R. Genomics in multiple sclerosis—current state and future directions. J. Neuroimmunol. 187, 1–8 (2007).
pubmed: 17400297
Ratzer, R. et al. Gene expression analysis of relapsing—remitting, primary progressive and secondary progressive multiple sclerosis. Mult. Scler. 19, 1841–1848 (2013).
pubmed: 24085340
Safari-alighiarloo, N., Rezaei-tavirani, M. & Taghizadeh, M. Network-based analysis of differentially expressed genes in cerebrospinal fluid (CSF) and blood reveals new candidate genes for multiple sclerosis. PeerJ. 4, 1–22 (2016).
Vanderlugt, C. L. & Miller, S. D. Epitope spreading in immune-mediated diseases: implications for immunotherapy. Nat. Rev. Immunol. 2, 85–95 (2002).
pubmed: 11910899
Getts, D. R. et al. Microparticles bearing encephalitogenic peptides induce T-cell tolerance and ameliorate experimental autoimmune encephalomyelitis. Nat. Biotechnol. 30, 1217–1224 (2012).
pubmed: 23159881 pmcid: 3589822
Hunter, Z. et al. A biodegradable nanoparticle platform for the induction of antigen-specific immune tolerance for treatment of autoimmune disease. ACS Nano. 4, 2148–2160 (2014).
Casey, L. M. et al. Conjugation of transforming growth factor beta to antigen-loaded poly(lactide- co -glycolide) nanoparticles enhances efficiency of antigen-specific tolerance. Bioconjug. Chem. 29, 813–823 (2018).
pubmed: 29148731
Hachim, D. et al. Effects of aging upon the host response to implants. J. Biomed. Mater. Res. 105, 1281–1292 (2017).
Orellano, L. A. A. et al. Upregulation of foreign body response in obese mice. Obesity 26, 531–539 (2018).
pubmed: 29377630
Boersema, G. S. A. et al. Monocyte subsets in blood correlate with obesity related response of macrophages to biomaterials in vitro. Biomaterials 109, 32–39 (2016).
pubmed: 27662579
Oakes, R. S. et al. Metastatic conditioning of myeloid cells at a subcutaneous synthetic niche reflects disease progression and predicts therapeutic outcomes. Cancer Res. 80, 602–612 (2019).
pubmed: 31662327
Morris, A. H. et al. Engineered niches to analyze mechanisms of metastasis and guide precision medicine. Cancer Res. https://doi.org/10.1158/0008-5472.CAN-20-0079 (2020).
doi: 10.1158/0008-5472.CAN-20-0079 pubmed: 32409307
Jones, G. W., Hill, D. G. & Jones, S. A. Understanding immune cells in tertiary lymphoid organ development: it is all starting to come together. Front. Immunol. 7, 1–13 (2016).
Geurtsvankessel, C. H., Hammad, H., Neyt, K. & Lambrecht, B. N. Tertiary lymphoid organs in infection and autoimmunity. Trends Immunol. 33, 297–305 (2012).
pubmed: 22622061 pmcid: 7106385
Nayar, S. et al. Immunofibroblasts are pivotal drivers of tertiary lymphoid structure formation and local pathology. Proc. Natl Acad. Sci. USA 116, 13490–13497 (2019).
pubmed: 31213547
Mittal, S. et al. Lymphoid aggregates that resemble tertiary lymphoid organs define a specific pathological subset in metal- on-metal hip replacements. PLoS ONE 8, e63470 (2013).
pubmed: 23723985 pmcid: 3665779
Casella, G. et al. A serine protease inhibitor suppresses autoimmune neuroinflammation by activating the STING/IFN- β axis in macrophages. Cell. Mol. Immunol. 17, 3–5 (2020).
Bailey, S. L., Schreiner, B., Mcmahon, E. J. & Miller, S. D. CNS myeloid DCs presenting endogenous myelin peptides ‘ preferentially’ polarize CD4 + T H -17 cells in relapsing EAE. Nat. Immunol. 8, 172–180 (2007).
pubmed: 17206145
Getts, D. R. et al. Therapeutic inflammatory monocyte modulation using immune-modifying microparticles. Sci. Transl. Med. 6, 219ra7 (2014).
pubmed: 24431111 pmcid: 3973033
King, I. L., Dickendesher, T. L. & Segal, B. M. Circulating Ly-6C+ myeloid precursors migrate to the CNS and play a pathogenic role during autoimmune demyelinating disease. Blood 113, 3190–3198 (2009).
pubmed: 19196868 pmcid: 2665891
Fletcher, J. M., Lalor, S. J., Sweeney, C. M., Tubridy, N. & Mills, K. H. G. T cells in multiple sclerosis and experimental autoimmune encephalomyelitis. Clin. Exp. Immunol. 162, 1–11 (2010).
pubmed: 20682002 pmcid: 2990924
Yoshimura, S. et al. IL-9 controls central nervous system autoimmunity by suppressing GM-CSF production. J. Immunol. 204, 531–539 (2020).
pubmed: 31852750
Billiau, A. & Matthys, P. Modes of action of Freund’s adjuvants in experimental models of autoimmune diseases. J. Leukoc. Biol. 70, 849–860 (2001).
pubmed: 11739546
Azarin, S. M. et al. In vivo capture and label-free detection of early metastatic cells. Nat. Commun. 6, 8094 (2015).
pubmed: 26348915 pmcid: 4563812
Aguado, B. A. et al. Extracellular matrix mediators of metastatic cell colonization characterized using scaffold mimics of the pre-metastatic niche. Acta Biomater. 33, 13–24 (2016).
pubmed: 26844426 pmcid: 4777643
Derfuss, T. Personalized medicine in multiple sclerosis: hope or reality? BMC Med. 10, 1–5 (2012).
Bushnell, G. G. et al. Biomaterial scaffolds recruit an aggressive population of metastatic tumor cells in vivo. Cancer Res. 79, 2042–2053 (2019).
pubmed: 30808673 pmcid: 6467791
Morris, A. H., Mahal, R. S., Udell, J., Wu, M. & Kyriakides, T. R. Multicompartment drug release system for dynamic modulation of tissue responses. Adv. Healthc. Mater. 6, 1700370 (2017).
Morris, A. H. et al. Decellularized materials derived from TSP2-KO mice promote enhanced neovascularization and integration in diabetic wounds. Biomaterials 169, 61–71 (2018).
pubmed: 29631168 pmcid: 5933884
Miller, S. D., Karpus, W. J. & Davidson, T. S. Experimental autoimmune encephalomyelitis in the mouse. Curr. Protoc. Immunol. 77, 15.1.1–15.1.18 (2007).
Aguado, B. A. et al. Biomaterial scaffolds as pre-metastatic niche mimics systemically alter the primary tumor and tumor microenvironment. Adv. Healthc. Mater. 7, 1700903 (2018).
McCarthy, D. P. et al. An antigen-encapsulating nanoparticle platform for TH1/17 immune tolerance therapy. Nanomed. Nanotechnol. Biol. Med. 13, 191–200 (2017).

Auteurs

Aaron H Morris (AH)

Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.

Kevin R Hughes (KR)

Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.

Robert S Oakes (RS)

Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.

Michelle M Cai (MM)

Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA.

Stephen D Miller (SD)

Department of Microbiology-Immunology and Interdepartmental Immunobiology Center, Northwestern University Feinberg School of Medicine, Chicago, IL, USA.

David N Irani (DN)

Department of Neurology, University of Michigan Medical School, Ann Arbor, MI, USA.

Lonnie D Shea (LD)

Department of Biomedical Engineering, University of Michigan, Ann Arbor, MI, USA. ldshea@umich.edu.
Department of Chemical Engineering, University of Michigan, Ann Arbor, MI, USA. ldshea@umich.edu.

Articles similaires

[Redispensing of expensive oral anticancer medicines: a practical application].

Lisanne N van Merendonk, Kübra Akgöl, Bastiaan Nuijen
1.00
Humans Antineoplastic Agents Administration, Oral Drug Costs Counterfeit Drugs

Smoking Cessation and Incident Cardiovascular Disease.

Jun Hwan Cho, Seung Yong Shin, Hoseob Kim et al.
1.00
Humans Male Smoking Cessation Cardiovascular Diseases Female
Humans United States Aged Cross-Sectional Studies Medicare Part C
1.00
Humans Yoga Low Back Pain Female Male

Classifications MeSH